Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Asparagine Metabolism Empowers Group A Streptococcus Infection

By BiotechDaily International staff writers
Posted on 30 Jan 2014
Image: Photomicrograph (900x) of Streptococcus pyogenes bacteria, viewed using Pappenheim\'s stain (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Photomicrograph (900x) of Streptococcus pyogenes bacteria, viewed using Pappenheim\'s stain (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Micrograph (H&E stain) of necrotizing fasciitis, showing necrosis (center of image) of the dense connective tissue, i.e., fascia, interposed between fat lobules (top-right and bottom-left of image) (Photo courtesy of Wikimedia Commons).
Image: Micrograph (H&E stain) of necrotizing fasciitis, showing necrosis (center of image) of the dense connective tissue, i.e., fascia, interposed between fat lobules (top-right and bottom-left of image) (Photo courtesy of Wikimedia Commons).
The bacteria that cause the frightening syndrome called "flesh-eating disease" have been found to be stimulated by the amino acid asparagine and inhibited by the chemotherapeutic enzyme asparaginase, which destroys asparagine.

Necrotizing fasciitis or NF, commonly known as "flesh-eating disease" is a rare infection of the deeper layers of skin and subcutaneous tissues, which quickly spreads across the fascial plane within the subcutaneous tissue. Individuals having compromised immune systems (due to conditions like diabetes, cancer, etc.) have greater risk of developing NF. It is a severe disease of sudden onset and is usually treated immediately with high doses of intravenous antibiotics. "Flesh-eating disease" is a misnomer, as the bacteria involved—most frequently Streptococcus pyogenes, or Group A Streptococcus (GAS)—do not actually "eat" the tissue. They cause the destruction of skin and muscle by releasing toxins, which include streptococcal pyogenic exotoxins.

Investigators at the Hebrew University of Jerusalem (Israel) reported in the January 16, 2014, issue of the journal Cell that during adherence to host cells, GAS releases streptolysin toxins, which create endoplasmic reticulum stress in the host cells. This stress causes an increase in the expression of the enzyme asparagine synthetase and the production of asparagine. The released asparagine is sensed by the bacteria, which induces altered expression of about 17% of the bacterial genes.

Asparaginase, a widely used chemotherapeutic agent, was found to block GAS growth in human blood and prevented GAS proliferation in a mouse model. To date asparaginase has not been used to treat GAS infections.

The Yissum Research Development Company (Jerusalem, Israel), the technology transfer arm of the Hebrew University of Jerusalem, has registered a patent for this discovery and is seeking commercial partners to help develop effective therapies against invasive Streptococcus infections.

Related Links:

Hebrew University of Jerusalem
Yissum Research Development Company



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.